Log in to search using one of your social media accounts:

 

Mature results favor pembrolizumab as second-line treatment for bladder cancer
(European Society for Medical Oncology) Mature results from the KEYNOTE-045 trial to be presented today at the ESMO 2017 Congress in Madrid have confirmed significantly longer survival in patients with advanced urothelial cancer who receive the checkpoint inhibitor pembrolizumab after initial chemotherapy, compared to an alternative chemotherapy regimen. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 10, 2017 Category: Cancer & Oncology Source Type: news

Urine test UroMark could save NHS millions
Developed by researchers at University College London, UroMark can detect bladder cancer in 98 per cent of cases, a figure equivalent to the results of cystoscopies. (Source: the Mail online | Health)
Source: the Mail online | Health - September 9, 2017 Category: Consumer Health News Source Type: news

Adding modified herpes virus to immunotherapy shows promise for treating advanced melanoma
FINDINGSIn a two-year study at UCLA, nearly two-thirds of people with advanced melanoma responded positively to a treatment that combines the immunotherapy drug pembrolizumab with a herpes virus called talimogene laherpareovec, or T-VEC. Researchers led by Dr. Antoni Ribas found that the treatment ’s side effects were manageable, and comparable to side effects for people who took either pembrolizumab or T-VEC as a standalone treatment.BACKGROUNDUCLA scientists are testing the combination of pembrolizumab (marketed as Keytruda) and T-VEC (marketed as Imlygic) as a treatment option for people with advanced melanoma tha...
Source: UCLA Newsroom: Health Sciences - September 7, 2017 Category: Universities & Medical Training Source Type: news

Sharks with frickin' lasers: Gold nanoparticles fry cancer on glowing mice
(University of Colorado Anschutz Medical Campus) A University of Colorado Cancer Center study takes a new approach to killing cancer: Why not fry it into oblivion with vibrating gold nanoparticles? Results are published online ahead of print in the journal Bladder Cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 30, 2017 Category: International Medicine & Public Health Source Type: news

Study highlights new link between gene fusion and bladder and brain cancer
(University of Warwick) A study by the University of Warwick sheds new light on gene fusion in bladder and brain cancer.Researchers have found that a previously overlooked part of a specific gene fusion has a worsening effect on cancer cells. They have also found that preventing cell 'signalling' from this particular fusion may not be an effective route for future cancer treatment research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 29, 2017 Category: Cancer & Oncology Source Type: news

Bristol-Myers, Daiichi Sankyo to test Opdivo combo for cancers
(Reuters) - Bristol-Myers Squibb Co and Daiichi Sankyo said they were evaluating a combination of Bristol-Myers' immuno-oncology drug, Opdivo, with the Japanese company's experimental drug in patients with breast and bladder cancers. (Source: Reuters: Health)
Source: Reuters: Health - August 28, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

New hope for victims of 'Cinderella' bladder cancer
Atezolizumab, can help those with an advanced form of the disease survive an average of almost 16 months compared to a survival rate of only 7.9 months for patients on chemotherapy. (Source: the Mail online | Health)
Source: the Mail online | Health - August 19, 2017 Category: Consumer Health News Source Type: news

Nanotech, immunotherapy combo vaccinates mouse against cancer
Researchers from Duke University combined an FDA-approved cancer immunotherapy with gold nanostars to boost the cancer-killing abilities of both therapies, according to a study published this week in Scientific Reports. The combination therapy cured two mice and vaccinated one against bladder cancer, the team reported. Get the full story at our sister site, Drug Delivery Business News. The post Nanotech, immunotherapy combo vaccinates mouse against cancer appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 18, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Oncology Pharmaceuticals Research & Development Duke University Source Type: news

Another Study Ties Pioglitazone to Bladder Cancer Risk (CME/CE)
(MedPage Today) -- Risk emerged within first 2 years; attenuated after discontinuing (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - August 10, 2017 Category: Pediatrics Source Type: news

Bladder Preservation Yields Poorer Survival in Urothelial Carcinoma
In patients with stage II to III urothelial carcinoma, bladder-preservation therapy was associated with poorer overall survival compared with radical cystectomy, according to a database study. (Source: CancerNetwork)
Source: CancerNetwork - August 6, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Bladder Cancer Genitourinary Cancers News Source Type: news

UK Finds Roche Bladder Cancer Drug Too Costly for Routine Use UK Finds Roche Bladder Cancer Drug Too Costly for Routine Use
Britain's healthcare cost-effectiveness agency NICE has decided Roche's new immunotherapy drug Tecentriq (atezolizumab) is too expensive to justify its routine use to treat bladder cancer, but still hopes it can be used in certain circumstances.Reuters Health Information (Source: Medscape Urology Headlines)
Source: Medscape Urology Headlines - August 4, 2017 Category: Urology & Nephrology Tags: Hematology-Oncology News Source Type: news

Urothelial Cancer Response to Neoadjuvant Chemo Varies by Histologic Variant
Certain histologic variants of urothelial bladder cancer benefit more from neoadjuvant chemotherapy, according to a new study. (Source: CancerNetwork)
Source: CancerNetwork - August 3, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Bladder Cancer Genitourinary Cancers News Source Type: news

Breakthrough in tackling aggressive cancers
Finding could lead to new treatments Related items fromOnMedica Nasopharyngeal carcinoma and sinus cancer Underused cancer test could improve treatment of colon cancer Blood test may pick up bladder cancer ’s return before symptoms appear Tall men at higher risk of aggressive prostate cancer UK spends 20% less on cancer treatment than rest of EU (Source: OnMedica Latest News)
Source: OnMedica Latest News - August 3, 2017 Category: UK Health Source Type: news

UK finds Roche bladder cancer drug too costly for routine use
LONDON (Reuters) - Britain's healthcare cost-effectiveness agency NICE has decided Roche's new immunotherapy drug Tecentriq is too expensive to justify its routine use to treat bladder cancer, but still hopes it can be used in certain circumstances. (Source: Reuters: Health)
Source: Reuters: Health - August 2, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Drug Safety Communication: Update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer
[6-15-2011] The U.S. Food and Drug Administration (FDA) is informing the public that use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 1, 2017 Category: Drugs & Pharmacology Source Type: news

Immediate Chemotherapy After TURBT Reduces NMIBC Recurrence Risk
An immediate instillation of chemotherapy with mitomycin C following transurethral resection of a bladder tumor reduced the risk of recurrence of non –muscle-invasive bladder cancer (NMIBC). (Source: CancerNetwork)
Source: CancerNetwork - July 24, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Bladder Cancer Genitourinary Cancers News Source Type: news

Immune cells the missing ingredient in new bladder cancer treatment
(University of British Columbia) New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 24, 2017 Category: Cancer & Oncology Source Type: news

Roche's Tecentriq receives positive opinion from EU medicines agency
ZURICH (Reuters) - A European Medicines Agency (EMA) panel said on Friday it has recommended Roche's immunotherapy Tecentriq as a treatment for advanced bladder and lung cancer, setting the stage for European Commission approval this year. (Source: Reuters: Health)
Source: Reuters: Health - July 22, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Noninvasive Urine Test Predicts Bladder Cancer Recurrence Noninvasive Urine Test Predicts Bladder Cancer Recurrence
A new noninvasive test was more predictive of bladder cancer recurrence than standard cytology and cystoscopy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 21, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

CHMP recommends EU approval for Roche ’s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer
Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for TECENTRIQ ® (atezolizumab) as a monotherapy for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) after they have been previously treated with chemotherapy. (Source: Roche Media News)
Source: Roche Media News - July 21, 2017 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval for Roche ’s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer
Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for TECENTRIQ ® (atezolizumab) as a monotherapy for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) after they have been previously treated with chemotherapy. (Source: Roche Investor Update)
Source: Roche Investor Update - July 21, 2017 Category: Pharmaceuticals Source Type: news

Bowel, bladder and stomach cancer warning - THIS habit is putting Britons at risk
SMOKING increases the risk of at least 14 cancers including lung cancer - one of England ’s major killers and dramatically increases the risk of heart disease. (Source: Daily Express - Health)
Source: Daily Express - Health - July 19, 2017 Category: Consumer Health News Source Type: news

Bowel, bladder and stomach cancer warning - THIS habit is putting you at risk
SMOKING increases the risk of at least 14 cancers including lung cancer - one of England ’s major killers and dramatically increases the risk of heart disease. (Source: Daily Express - Health)
Source: Daily Express - Health - July 18, 2017 Category: Consumer Health News Source Type: news

TERT Urine Test Can Help Predict Bladder Cancer Recurrence
A urine test of telomerase reverse transcriptase (TERT) was found to be a reliable predictor of recurrence in non –muscle-invasive bladder cancer, according to a new study. (Source: CancerNetwork)
Source: CancerNetwork - July 12, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Bladder Cancer Genitourinary Cancers News Source Type: news

Bladder cancer test can predict the disease for 80%
Researchers from University Hospital of Lyon, France, have developed a machine that can quickly measure levels of a faulty protein in human urine known as TERT, a sign of cancer. (Source: the Mail online | Health)
Source: the Mail online | Health - July 7, 2017 Category: Consumer Health News Source Type: news

Simple test can predict bladder cancer recurrence
Researchers from the University Hospital of Lyon developed a simple urine test to more accurately predict the recurrence of bladder cancer. (Source: Health News - UPI.com)
Source: Health News - UPI.com - July 7, 2017 Category: Consumer Health News Source Type: news

Simple test predicts return of bladder cancer
(Cancer Research UK) Scientists have devised a simple test for an earlier and more accurate warning of returning bladder cancer than existing methods, according to research published in the British Journal of Cancer today. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 7, 2017 Category: Cancer & Oncology Source Type: news

Blood test may pick up bladder cancer ’s return before symptoms appear
Offers tantalising prospect of being able to treat disease at earlier stage Related items fromOnMedica Blood test could predict likelihood of cancer returning Blood test to monitor effectiveness of cancer treatments Blood test could help predict response to lung cancer treatment Cheap blood test could boost prostate cancer treatment Underused cancer test could improve treatment of colon cancer (Source: OnMedica Latest News)
Source: OnMedica Latest News - July 7, 2017 Category: UK Health Source Type: news

Bladder cancer symptoms - simple test could indicate deadly disease
BLADDER cancer usually reveals itself with one main symptom - urine in the blood - but now experts have found a new way to detect the disease. (Source: Daily Express - Health)
Source: Daily Express - Health - July 6, 2017 Category: Consumer Health News Source Type: news

BeiGene commences dosing in Phase II trial of BGB-A317 to treat urothelial cancer
Global biotechnology company BeiGene has commenced dosing patients in a new Phase II trial of its investigational anti-PD-1 antibody, BGB-A317, in patients with urothelial cancer (UC), more commonly known as bladder cancer, in China. (Source: Drug Development Technology)
Source: Drug Development Technology - July 6, 2017 Category: Pharmaceuticals Source Type: news

Physical Inactivity Linked to Kidney, Bladder Cancers
Lack of participation in any regular recreational physical activity was associated with a significantly increased risk for both bladder and renal cancers. (Source: CancerNetwork)
Source: CancerNetwork - June 29, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Bladder Cancer News Renal Cell Carcinoma Source Type: news

When Can a Doctor Help Your Back Pain?
Treatment TermsBack pain TagsBack pain Sub-Title Answers to Common Back Pain Questions Overview More than eight in 10 people will experience back pain at some point in their lives. In most cases, the pain goes away over time. If your back pain is severe or does not improve, you may need medical care. Here are answers to some common questions about back pain and tips on when to seek help. Content Blocks Header Why Does My Back Hurt? ContentThere are various reasons why your back can hurt, including muscle pain, disc pain, joint pain, or nerve pain. In most cases, these are not harmful or dangerous. “There are...
Source: dukehealth.org: Duke Health News - June 28, 2017 Category: Consumer Health News Authors: mf205 at duke.edu Source Type: news

Sitka Biopharma to initiate Phase I trial of STK-01 to treat bladder cancer
Canada-based biotechnology firm Sitka Biopharma has entered an agreement with Cancer Research UK and Cancer Research Technology (CRT) to start a Phase I clinical trial of STK-01 for treatment of patients with bladder cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - June 27, 2017 Category: Pharmaceuticals Source Type: news

Robot-assisted Implantation of Brachytherapy Catheters Promising in Bladder Cancer Robot-assisted Implantation of Brachytherapy Catheters Promising in Bladder Cancer
Robot-assisted laparoscopic (RAL) implantation of brachytherapy catheters (BTC) is a minimally invasive alternative to open retropubic surgery, researchers from the Netherlands report.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - June 27, 2017 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Seattle Cancer Center Opens Latest Mesothelioma Clinical Trial
The Seattle Cancer Care Alliance has opened a phase II clinical trial involving durvalumab, the promising immunotherapy drug, in combination with chemotherapy for the first-line treatment of unresectable pleural mesothelioma. The U.S. Food and Drug Administration (FDA) already granted accelerated approval to durvalumab in May for the treatment of bladder cancer. Researchers have also lauded the drug for its effectiveness in earlier lung cancer clinical trials. “We have every reason to believe it will be effective with mesothelioma, too,” Dr. Bernardo Goulart, chief trial investigator and medical oncologist at t...
Source: Asbestos and Mesothelioma News - June 27, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: cancer in seattle doctor Bernardo Goulart mesothelioma clinical trials mesothelioma in seattle mesothelioma treatment seattle cancer care alliance Source Type: news

First-Line Pembrolizumab for Urothelial Carcinoma Offers Durable Responses
After extended follow-up, the KEYNOTE-052 study has shown that first-line pembrolizumab offers durable responses and no new safety signals in patients with cisplatin-ineligible advanced urothelial cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 22, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Bladder Cancer Genitourinary Cancers News Source Type: news

Epacadostat/Pembrolizumab Promising in Advanced Bladder Cancer in Early Trial
The combination of pembrolizumab and the IDO1 inhibitor epacadostat was active and generally well tolerated in patients with urothelial carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - June 21, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Bladder Cancer Genitourinary Cancers News Source Type: news

'Couch Potatoes' May Face Higher Risk of Kidney, Bladder Cancers
Title: 'Couch Potatoes' May Face Higher Risk of Kidney, Bladder CancersCategory: Health NewsCreated: 6/15/2017 12:00:00 AMLast Editorial Review: 6/16/2017 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - June 16, 2017 Category: Cancer & Oncology Source Type: news

'Couch Potatoes' May Face Higher Risk of Kidney, Bladder Cancers
Researchers say get moving, and point to national exercise guidelines (Source: Cancercompass News: Other Cancer)
Source: Cancercompass News: Other Cancer - June 16, 2017 Category: Cancer & Oncology Source Type: news

Sedentary Lifestyle May Up Risk of Renal, Bladder Cancers
73 percent increased risk for bladder cancer, 77 percent increased risk for renal (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 16, 2017 Category: Cancer & Oncology Tags: Family Medicine, Geriatrics, Gynecology, Internal Medicine, Nephrology, Nursing, Oncology, Pathology, Urology, Journal, Source Type: news

‘ Couch Potatoes ’ May Face Higher Risk of Kidney, Bladder Cancers
Researchers say get moving, and point to national exercise guidelines (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 15, 2017 Category: Cancer & Oncology Tags: Oncology, Sports Medicine, News, Source Type: news

' Couch Potatoes' May Face Higher Risk of Kidney, Bladder Cancers
Researchers say get moving, and point to national exercise guidelines Source: HealthDay Related MedlinePlus Pages: Bladder Cancer, Healthy Living, Kidney Cancer (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - June 15, 2017 Category: Consumer Health News Source Type: news

' Couch Potatoes' May Face Higher Risk of Kidney, Bladder Cancers
THURSDAY, June 15, 2017 -- Add greater risk of kidney and bladder cancer to the long list of why a lifetime of sitting on the sofa isn't good for your health, a new study suggests. Specifically, lifetime recreational inactivity was associated with... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 15, 2017 Category: General Medicine Source Type: news

Invasive Bladder Cancer: Surgery Not Always the Best Option (CME/CE)
(MedPage Today) -- Radiation-based management offers equally good survival outcomes (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 7, 2017 Category: Hematology Source Type: news

Why Access To Planned Parenthood Is Vital And Must Be Protected
  In 2007, Amanda Ream ― from Coatesville, Pennsylvania ― was uninsured, recently diagnosed with a chronic, painful bladder issue, and in graduate school at Widener University in Chester when she turned to Planned Parenthood for her health care. She could not get health insurance because of her “pre-existing condition” and could not afford to pay for her basic health care, like family planning and cancer screenings. She turned to Planned Parenthood for high-quality, affordable, compassionate health care. When I met with Amanda, at the Planned Parenthood Upper Darby Health Center, she told me Planned Pa...
Source: Healthy Living - The Huffington Post - June 7, 2017 Category: Consumer Health News Source Type: news

Symptoms Before and After TURBT and Intravesical Epirubicin Symptoms Before and After TURBT and Intravesical Epirubicin
How do patient symptoms compare both before and after this commonly used treatment for bladder cancer?Urologic Nursing (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 7, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

10 Facts Women Should Know About Endometrial Cancer
The most common cancer of the reproductive organs in American women is endometrial cancer. The American Cancer Society estimates that for the year 2017, around 61,380 new cases of cancer of the body of the uterus will be diagnosed and about 10,920 women will die from cancers of the uterine body. These figures include both endometrial cancers and uterine sarcomas. Since endometrial cancer is a fairly common cancer in women, the more women know the facts about this disease, the greater their chance of knowing what symptoms to be aware of in order to have it diagnosed as early as possible, improving the likelihood of surviva...
Source: Healthy Living - The Huffington Post - June 5, 2017 Category: Consumer Health News Source Type: news

Nivolumab Approved for Bladder Cancer by European Commission Nivolumab Approved for Bladder Cancer by European Commission
The EC approved nivolumab for adults with locally advanced unresectable or metastatic urothelial carcinoma that has failed to respond to prior platinum-containing therapy.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 5, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

9 Reasons To Drink Water That Have Nothing To Do With Being Thirsty
Exactly how much water people need to drink each day to stay hydrated is a subject of debate. You’ve likely heard that you need at least six to eight glasses a day, but the real figure depends on other factors. How much activity you get, the climate you live in and how much water you get from sources like fruits and vegetables all matters. The good news is that as long as you make water your main beverage, drink when you’re thirsty and consume it with meals, you don’t need to get caught up tallying glasses, according to the U.S. Centers for Disease Control and Prevention. But keeping properly hydrate...
Source: Healthy Living - The Huffington Post - June 2, 2017 Category: Consumer Health News Source Type: news